abc biopply ag
SME
abc biopply ag
Description
abc biopply humanized disease models predict patient response to treatment
Our proprietary technology creates hundreds of miniature patient organs in a laboratory setting, using both healthy and diseased tissues. Our innovative models bridge the gap in predictability between the lab and the clinic.
Our proprietary technology creates hundreds of miniature patient organs in a laboratory setting, using both healthy and diseased tissues. Our innovative models bridge the gap in predictability between the lab and the clinic.
abc biopply ag
Address
Weissensteinstrasse 81 CH-4500 Solothurn Switzerland
Contact
service@biopply.com
Description
abc biopply humanized disease models predict patient response to treatment
Our proprietary technology creates hundreds of miniature patient organs in a laboratory setting, using both healthy and diseased tissues. Our innovative models bridge the gap in predictability between the lab and the clinic.
Our proprietary technology creates hundreds of miniature patient organs in a laboratory setting, using both healthy and diseased tissues. Our innovative models bridge the gap in predictability between the lab and the clinic.
Matchmaking
Connect with abc biopply ag
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways